found that HJURP regulated the cyclin-dependent kinase inhibitor 1 (CDKN1A) through the GSK3/JNK signaling pathway in prostate cancer, and affected the growth of tumor cells27. This evidence concerns the gene MAPK8 and prostate carcinoma.